ACHL Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 geg. 2024 @ 23:00):

Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors...

Stats
Dzisiejszy wolumen	185 038
Średni wolumen	721 446
Kapitalizacja rynkowa	33.02M
EPS	$0 ( 2024-04-02 )
Następna data zysków	( $-0.460 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.460
ATR14	$0.00400 (0.50%)

Wolumen Korelacja

Długi: -0.15 (neutral)

Krótki: -0.01 (neutral)

Signal:(37.945) Neutral

Achilles Therapeutics plc Korelacja

10 Najbardziej pozytywne korelacje
STER	0.94
SVAC	0.939
AGLE	0.938
ELEV	0.925
ALZN	0.922
GANX	0.922
TSVT	0.918
PAIC	0.913
SEDG	0.912
ALGT	0.911

10 Najbardziej negatywne korelacje
TSBK	-0.92
BLTE	-0.918
NETE	-0.912
MITA	-0.911
FANH	-0.906
SGII	-0.905
LOPE	-0.901
CHPM	-0.899
MTSI	-0.898
LWAC	-0.897

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Achilles Therapeutics plc Korelacja - Waluta/Towar

-0.08
( neutral )

0.20
( neutral )

0.00
( neutral )

-0.16
( neutral )

0.00
( neutral )

-0.49
( neutral )

Achilles Therapeutics plc Finanse

Annual	2023
Przychody:	$0
Zysk brutto:	$-4.73M (0.00 %)
EPS:	$-1.750

FY	2023
Przychody:	$0
Zysk brutto:	$-4.73M (0.00 %)
EPS:	$-1.750

FY	2022
Przychody:	$0
Zysk brutto:	$-3.69M (0.00 %)
EPS:	$-1.820

FY	2021
Przychody:	$0.00
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-3.36

Financial Reports:

No articles found.

Achilles Therapeutics plc

Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. The company was founded in 2016 and is headquartered in London, the United Kingdom.

Aktualne aktualizacje dla Achilles Therapeutics plc [ACHL]

Upcoming Earnings Alert